In cases of fPCT, however, where URO-D activity is abnormally low due to heterozygous mutation, even modest increases in hepatic iron concentration could result in inhibitor formation sufficient to produce clinical symptoms of PCT. This evidence concerns the gene UROD and porphyria cutanea tarda.